Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06274554 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

Study acronym: FUN-CD
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study description expanded, about 31 words
    • Site contact updated
    v5
  2. Eligibility criteria shortened, about 58 words
    • Study description expanded, about 6 words
    • Site contact updated
    v4
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Aug 2024 to Oct 4, 2024
    • Site details revised
    v3
  4. Start date: Jun 2024 to Aug 2024
    • Eligibility criteria expanded, about 80 words
    • Study description shortened, about 13 words
    • Study title revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to start or are currently undergoing standard of care treatment and plan to dose-escalate an IL-23 therapy for their Crohn's disease. The main question it aims to assess is whether or not patient response to IL-23 therapies improve when simultaneously treated with fluconazole.
Trial Details
NCT Number NCT06274554
Lead Sponsor Weill Medical College of Cornell University
Collaborators: The Leona M. and Harry B. Helmsley Charitable Trust
Conditions
(from sponsor)		 Crohn's Disease, Inflammatory Bowel Diseases
Related terms Crohn Disease, Inflammatory Bowel Diseases
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov